Chondroitin sulfate proteoglycan 4 (CSPG4)

Chondroitin sulfate proteoglycan 4 (CSPG4) is a large, single-pass transmembrane proteoglycan characterized by an extensive extracellular domain decorated with chondroitin sulfate side chains, a transmembrane region, and a short intracellular tail. Originally described as a melanoma-associated antigen (MCSP or HMW-MAA), CSPG4 is highly expressed on various tumor cells—including melanoma, glioblastoma, sarcoma, and triple-negative breast cancer—while showing limited expression in normal adult tissues. CSPG4 lacks intrinsic kinase or catalytic activity, but acts as a scaffold, interacting with growth factors, integrins, matrix proteins, and receptor tyrosine kinases to promote activation of downstream oncogenic signaling cascades (notably MAPK and PI3K/AKT), thereby supporting tumor proliferation, migration, adhesion, ECM remodeling, and metastasis. Its restricted normal tissue distribution and key role in tumor biology make CSPG4 a prioritized target for therapeutic strategies such as monoclonal antibodies and CAR T-cell therapies in oncology.

Other names

MCSP (melanoma-associated chondroitin sulfate proteoglycan)NG2 (neuron-glial antigen 2, mainly in rodents)HMW-MAA (high molecular weight-melanoma associated antigen)melanoma chondroitin sulfate proteoglycan

Immune-mediated killing (antibody-, CAR T-, and bispecific killer engager-mediated cytotoxicity); Blockade of tumor cell proliferation and migration by antibody or genetic downregulation; Targeted delivery of cytotoxins to CSPG4+ cells (antibody-drug or radionuclide conjugates); Disruption of intracellular signaling pathways involved in oncogenesis (e.g., MAPK and PI3K/AKT) by interfering with CSPG4’s scaffold functions